Pfizer, GSK, Siemens and A*STAR form R&D consortium

Monday, June 24, 2013 03:13 PM

Pfizer Asia Pacific, GlaxoSmithKline and Siemens are founding members of the A*STAR R&D consortium program Innovative Processing of Specialties and Pharmaceuticals (iPSP). Launched by A*STAR's Institute of Chemical and Engineering Sciences (ICES), the consortium is a platform for pharmaceutical and specialty chemicals industry companies to address costs, regulatory compliance and responsiveness in production and processes to bring drugs to markets.

The program addresses the need to access emerging "next generation manufacturing" technologies that provide quantum change improvements in cost, quality, environmental impact and process robustness in pharmaceutical manufacturing processes. The advancement in technologies and adoption of best practices in processing technologies will help companies increase productivity and manpower development.

The program also offers a platform for members to interact, develop and grow the industry processing technology knowledge base by facilitating the technology transfer and manpower development in advanced chemical processing technologies. The program draws on established resources and capabilities at ICES. These include the Kilo Scale Laboratory, pilot scale multipurpose continuous plant and a development laboratory. The Institute's core skill areas, including chemistry, chemical engineering, analytics, control, formulation science and catalysis, form a basis for the development of innovative manufacturing approaches.

The program will see research activities undertaken in industrially relevant areas like process analytics (PAT), Quality by Design (Qbd) as well as continuous manufacturing systems.

In Singapore, the chemicals and energy industries accounted for around $78 billion or 34% of total manufacturing output in 2012. The consortium presents opportunities for companies to extend a presence in Singapore and leverage on its position into Asia.

"For Singapore manufacturing business to sustain global competitiveness, employing technological advancements in the areas of energy management and manufacturing operations is essential. The iPSP program provides a platform to move ideas in technology to real world solutions," said Mr. George Routhier, managing director, Pfizer Asia Pacific.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs